<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font23 { font-size : 23; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font30">the </span>
   <span class="font23">with </span>
   <span class="font16">effects </span>
   <span class="font15">[]. </span>
   <span class="font15">adverse </span>
   <span class="font15">for </span>
   <span class="font15">are </span>
   <span class="font14">treatment </span>
   <span class="font14">may </span>
   <span class="font14">neuropsychiatric </span>
   <span class="font14">The </span>
   <span class="font14">been </span>
   <span class="font13">patients </span>
   <span class="font13">which </span>
   <span class="font13">{background </span>
   <span class="font13">associated </span>
   <span class="font12">antiviral </span>
   <span class="font12">drugs </span>
   <span class="font12">have </span>
   <span class="font12">that </span>
   <span class="font12">events </span>
   <span class="font12">al. </span>
   <span class="font12">hepatitis </span>
   <span class="font12">margin </span>
   <span class="font12">not </span>
   <span class="font12">clinical </span>
   <span class="font12">use </span>
   <span class="font12">{border-style </span>
   <span class="font12">was </span>
   <span class="font12">has </span>
   <span class="font12">more </span>
   <span class="font12">px;} </span>
   <span class="font12">side </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">antiretroviral </span>
   <span class="font11">neuropathy </span>
   <span class="font11">other </span>
   <span class="font11">efavirenz </span>
   <span class="font11">most </span>
   <span class="font11">peripheral </span>
   <span class="font11">psychiatric </span>
   <span class="font11">reported </span>
   <span class="font11">were </span>
   <span class="font11">Neuropsychiatric </span>
   <span class="font11">from </span>
   <span class="font11">such </span>
   <span class="font11">chronic </span>
   <span class="font11">common </span>
   <span class="font11">compared </span>
   <span class="font11">similar </span>
   <span class="font11">therapy </span>
   <span class="font11">used </span>
   <span class="font11">combination </span>
   <span class="font11">drug </span>
   <span class="font11">due </span>
   <span class="font11">inhibitors </span>
   <span class="font11">mitochondrial </span>
   <span class="font11">oseltamivir </span>
   <span class="font11">this </span>
   <span class="font11">acyclovir </span>
   <span class="font11">nervous </span>
   <span class="font11">reverse </span>
   <span class="font11">DNA </span>
   <span class="font11">They </span>
   <span class="font11">agents </span>
   <span class="font11">disturbances </span>
   <span class="font11">nucleoside </span>
   <span class="font11">related </span>
   <span class="font11">risk </span>
   <span class="font11">studies </span>
   <span class="font11">symptoms </span>
   <span class="font11">system </span>
   <span class="font11">tenofovir </span>
   <span class="font11">these </span>
   <span class="font11">they </span>
   <span class="font11">transcriptase </span>
   <span class="font11">HIV </span>
   <span class="font11">after </span>
   <span class="font11">also </span>
   <span class="font11">but </span>
   <span class="font11">ribavirin </span>
   <span class="font11">treated </span>
   <span class="font10">abnormal </span>
   <span class="font10">acute </span>
   <span class="font10">central </span>
   <span class="font10">data </span>
   <span class="font10">inhibitor </span>
   <span class="font10">mechanism </span>
   <span class="font10">myopathy </span>
   <span class="font10">published </span>
   <span class="font10">px; </span>
   <span class="font10">study </span>
   <span class="font10">though </span>
   <span class="font10">two </span>
   <span class="font10">{font-family </span>
   <span class="font10">all </span>
   <span class="font10">association </span>
   <span class="font10">cause </span>
   <span class="font10">direct-acting </span>
   <span class="font10">discontinuation </span>
   <span class="font10">during </span>
   <span class="font10">font-size </span>
   <span class="font10">include </span>
   <span class="font10">integrase </span>
   <span class="font10">patient </span>
   <span class="font10">regimen </span>
   <span class="font10">regimens </span>
   <span class="font10">their </span>
   <span class="font10">tolerated </span>
   <span class="font10">toxicity </span>
   <span class="font10">well </span>
   <span class="font10">within </span>
   <span class="font10">Clin </span>
   <span class="font10">antivirals </span>
   <span class="font10">approved </span>
   <span class="font10">cases </span>
   <span class="font10">cohort </span>
   <span class="font10">containing </span>
   <span class="font10">depression </span>
   <span class="font10">double; </span>
   <span class="font10">effect </span>
   <span class="font10">fatigue </span>
   <span class="font10">fumarate </span>
   <span class="font10">including </span>
   <span class="font10">individuals </span>
   <span class="font10">initial </span>
   <span class="font10">initiation </span>
   <span class="font10">mechanisms </span>
   <span class="font10">monoamine </span>
   <span class="font10">reactions </span>
   <span class="font10">receptors, </span>
   <span class="font10">renal </span>
   <span class="font10">research </span>
   <span class="font10">than </span>
   <span class="font10">upon </span>
   <span class="font10">Inhibitors </span>
   <span class="font10">MAO </span>
   <span class="font10">South </span>
   <span class="font10">appear </span>
   <span class="font10">being </span>
   <span class="font10">between </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">case </span>
   <span class="font10">drugs, </span>
   <span class="font10">effects, </span>
   <span class="font10">events, </span>
   <span class="font10">first-line </span>
   <span class="font10">however, </span>
   <span class="font10">incidence </span>
   <span class="font10">inhibitors, </span>
   <span class="font10">interferon </span>
   <span class="font10">less </span>
   <span class="font10">mood </span>
   <span class="font10">neuropathy, </span>
   <span class="font10">only </span>
   <span class="font10">pronounced </span>
   <span class="font10">psychosis </span>
   <span class="font10">psychotropic </span>
   <span class="font10">safety </span>
   <span class="font10">significant </span>
   <span class="font10">sleep </span>
   <span class="font10">solid; </span>
   <span class="font10">some </span>
   <span class="font10">tolerability </span>
   <span class="font10">via </span>
   <span class="font10">virus </span>
   <span class="font10">whether </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">Cureus </span>
   <span class="font10">Efavirenz </span>
   <span class="font10">GABA-A </span>
   <span class="font10">HIV-infected </span>
   <span class="font10">However, </span>
   <span class="font10">NPAEs </span>
   <span class="font10">Peripheral </span>
   <span class="font10">Protease </span>
   <span class="font10">Psychiatric </span>
   <span class="font10">Valacyclovir </span>
   <span class="font10">active </span>
   <span class="font10">analogues </span>
   <span class="font10">anxiety </span>
   <span class="font10">attributed </span>
   <span class="font10">available </span>
   <span class="font10">better </span>
   <span class="font10">bold </span>
   <span class="font10">children </span>
   <span class="font10">commonly </span>
   <span class="font10">complications </span>
   <span class="font10">confusion, </span>
   <span class="font10">courier; </span>
   <span class="font10">depletion </span>
   <span class="font10">developed </span>
   <span class="font10">disoproxil </span>
   <span class="font10">dolutegravir </span>
   <span class="font10">drugs. </span>
   <span class="font10">efficacy </span>
   <span class="font10">em; </span>
   <span class="font10">factors </span>
   <span class="font10">first </span>
   <span class="font10">following </span>
   <span class="font10">frequent </span>
   <span class="font10">greater </span>
   <span class="font10">herpes </span>
   <span class="font10">human </span>
   <span class="font10">idiosyncratic </span>
   <span class="font10">increased </span>
   <span class="font10">influenza </span>
   <span class="font10">insomnia, </span>
   <span class="font10">interactions </span>
   <span class="font10">into </span>
   <span class="font10">its </span>
   <span class="font10">lamivudine </span>
   <span class="font10">likely </span>
   <span class="font10">many </span>
   <span class="font10">mild </span>
   <span class="font10">neurotoxicity </span>
   <span class="font10">new </span>
   <span class="font10">occur </span>
   <span class="font10">older </span>
   <span class="font10">one </span>
   <span class="font10">phase </span>
   <span class="font10">pro-drug </span>
   <span class="font10">profile </span>
   <span class="font10">psychosis, </span>
   <span class="font10">psychotic </span>
   <span class="font10">pt;} </span>
   <span class="font10">rare </span>
   <span class="font10">rates </span>
   <span class="font10">regarding </span>
   <span class="font10">report </span>
   <span class="font10">response </span>
   <span class="font10">search </span>
   <span class="font10">serotonin </span>
   <span class="font10">serum </span>
   <span class="font10">severe </span>
   <span class="font10">sofosbuvir-based </span>
   <span class="font10">telbivudine </span>
   <span class="font10">there </span>
   <span class="font10">treat </span>
   <span class="font10">trials </span>
   <span class="font10">who </span>
  </p>
 </body>
</html>
